Skip to main content
Premium Trial:

Request an Annual Quote

Prometheus Gets New VP of Dx R&D; Interleukin Genetics Appoints Medical Director; CombiMatrix Fleshes Out SAB; and More

Bruker AXS has promoted Bernard Kolodziej as vice president of finance. Kolodziej was originally hired by Bruker AXS in 1997 and has been CFO for the European operations of Bruker AXS since January 1999. Before joining the company, he held several operations and financial positions with the Siemens' X-ray business. He has a master's degree in business administration, finance, and production engineering from the Universityof Karlsruhein Germany.


Prometheus Laboratories has appointed Bruce Neri as vice president of diagnostics R&D, and ClydeShoresas vice president of marketing.

 

Neri joins Prometheus from Third Wave Technologies, where he was most recently senior vice president of R&D for its Invader technology. Prior to joining Third Wave, he was vice president of DNA probe development at Becton Dickinson. Shores served in various executive roles at companies such as Amgen and Abbott.


Interleukin Genetics has appointed Taha Keilani as medical director; Christopher Palatucci as senior director of business development and licensing; Paul Voegelin as director of operations and planning; and Gary Breton as DNA laboratory manager.

 

Keilani comes to Interleukin from Serono, where he was medical director of clinical development and regulatory affairs. Palatucci comes to Interleukin from Athena Diagnostics, where he was director of business development. Voegelin comes to Interleukin from Genuity Solutions, where he was director of operations. Breton comes to the company from Genome Therapeutics, where he was project manager and senior scientist.


AVI BioPharma has appointed Peter O'Hanley as senior vice president of clinical development and regulatory affairs, and Ray Cummings as vice president of business development.

 

O'Hanley comes to the company from Maxygen, where he was vice president of clinical development. He received his PhD and MD degrees from the Medical University of South Carolina, and obtained his MPH at the Universityof California, Berkeley.

 

Cummings comes to AVI from Cummings Consulting, where he was founder and president. Before founding the firm, he was a vice president of business development at Aradigm. Cummings received his MBA from the Universityof California, Berkeley. He also received an MS from HarvardUniversityin biochemistry and molecular biology, and a BS in biological sciences from StanfordUniversity.


Orion Genomics has promoted Jeffrey Jeddeloh to be director of biomarker discovery and detection. Jeddeloh's primary responsibility will be to discover and develop assays for detecting epigenetic biomarkers linked to certain cancers.

 

Jeddeloh joined Orion from the United States Army where he served as a principal investigator at the US Army Medical Research Institute of Infectious Diseases. He received his PhD in molecular genetics from WashingtonUniversityin St. Louis.


CombiMatrix has named Mark Kay to its scientific advisory board. Kay is professor in the departments of pediatrics and genetics, and the director of the program in human gene therapy at the Stanford University School of Medicine.
The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.